Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Alexander Drilon

Stock and Other Ownership Interests: Treeline Bio

Honoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, Remedica Ltd

Consulting or Advisory Role: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, i3 Health, MonteRosa

Research Funding: Pfizer (Inst), Exelixis (Inst), GlaxoSmithKlein (Inst), Teva (Inst), Taiho (Inst), PharmaMar (Inst)

Patents, Royalties, Other Intellectual Property: Selpercatinib-Osimertinib (filed/pending), Wolters Kluwer, Merck, Puma, Merus, Boehringer Ingelheim

Vivek Subbiah

Consulting or Advisory Role: MedImmune, Helsinn Therapeutics, Loxo, R-Pharm, QED Therapeutics

Research Funding: Novartis (Inst), GlaxoSmithKline (Inst), NanoCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech/Roche (Inst), Berg Pharma (Inst), Bayer (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), AbbVie (Inst), MultiVir (Inst), Blueprint Medicines (Inst), Loxo (Inst), Vegenics (Inst), Takeda (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Biomedical (Inst), Inhibrx (Inst), Exelixis (Inst), Amgen (Inst), Turning Point Therapeutics (Inst)

Travel, Accommodations, Expenses: PharmaMar, Bayer, Novartis, Helsinn Therapeutics

Other Relationship: Medscape

Oliver Gautschi

Consulting or Advisory Role: Amgen (Inst), Lilly (Inst)

Other Relationship: Bayer, Pfizer, Roche, Merck, Lilly

Pascale Tomasini

Consulting or Advisory Role: AstraZeneca, Roche, Bristol Myers Squibb Foundation, Takeda, Amgen, Janssen

Travel, Accommodations, Expenses: Bristol Myers Squibb/Pfizer, AstraZeneca, Takeda

Filippo de Braud

Honoraria: Roche, Pfizer, BMS, Merck, MSD, Servier, Sanofi, Amgen Astellas BioPharma, Incyte

Consulting or Advisory Role: Roche, Incyte, EMD Serono, Bristol Myers Squibb, Nerviano Medical Sciences, Sanofi, Novartis Italy, NMS Medical Science, Menarini, AstraZeneca, Pierre Fabre

Research Funding: Novartis (Inst), Roche (Inst), Merck Serono (Inst), Pfizer (Inst), Servier, Philogen (Inst), Loxo (Inst), Tesaro (Inst), Nerviano Medical Sciences (Inst), Kymab (Inst), Bristol Myers Squibb/Medarex, Merck KGaA, Ignyta, MedImmune, Exelixis, Bayer Health, Daiichi Sankyo Europe GmbH, Incyte, Basilea Pharmaceutical, Janssen Oncology

Benjamin J. Solomon

Honoraria: Bristol Myers Squibb, AstraZeneca, Merck Sharp & Dohme, Roche/Genentech, Pfizer, Amgen (Inst)

Consulting or Advisory Role: Bristol Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Pfizer (Inst), Roche/Genentech, Amgen, Lilly, BeiGene, Takeda, GlaxoSmithKline (Inst), Novartis (Inst), Janssen

Research Funding: Sanofi (Inst)

Patents, Royalties, Other Intellectual Property: UpToDate

Daniel Shao-Weng Tan

Honoraria: Bristol Myers Squibb, Takeda, Novartis, Roche, Pfizer

Consulting or Advisory Role: Novartis, Merck, Loxo, AstraZeneca, Roche, Pfizer, C4 Therapeutics

Research Funding: Novartis (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst)

Travel, Accommodations, Expenses: Pfizer, Boehringer Ingelheim, Roche

Jürgen Wolf

Honoraria: AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, MSD, Novartis, Roche, Amgen, Bayer, Blueprint Medicines, Chugai Pharma Europe, Daiichi Sankyo Europe GmbH, Ignyta, Janssen, Lilly, Loxo, Loxo/Lilly, Pfizer, Seattle Genetics, Takeda

Consulting or Advisory Role: AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai Pharma, Ignyta, Lilly, MSD Oncology, Novartis, Pfizer, Roche, Janssen, Loxo/Lilly, Blueprint Medicines, Amgen, Takeda, Bayer, Daiichi Sankyo Europe GmbH, Seattle Genetics

Research Funding: Bristol Myers Squibb, Novartis, Pfizer, Janssen

Keunchil Park

Consulting or Advisory Role: AstraZeneca, Lilly, Ono Pharmaceutical, Bristol Myers Squibb, MSD, Merck KGaA, AbbVie, Daiichi Sankyo, Boehringer Ingelheim, JNJ, IMBdx, Geninus

Speakers' Bureau: Boehringer Ingelheim

Research Funding: AstraZeneca, MSD Oncology

Koichi Goto

Honoraria: Guardant Health, Janssen, Daiichi Sankyo Co Ltd, Amgen, Eisai, Bristol Myers Squibb K.K., AstraZeneca Japan, Chugai Pharma, Ono Pharmaceutical, Novartis, Lilly Japan, Boehringer Ingelheim, Takeda, Otsuka, Amoy Diagnostics, Bayer, Mertck

Consulting or Advisory Role: Takeda, Bayer, Lilly Japan, Amgen, Medpace, Janssen

Research Funding: Medical & Biological Laboratories Co Ltd, Kyowa Kirin Co Ltd, Kissei Pharmaceutical, Merck, Merus, Spectrum Pharmaceuticals, Shanghai HaiHe Pharmaceutical, MSD K.K., AstraZeneca Japan, Taiho Pharmaceutical, Chugai Pharma, Boehringer Ingelheim, Ono Pharmaceutical, Sumitomo Dainippon Pharma Co Ltd, Takeda, Eisai, Lilly Japan, Pfizer, Bristol-Myers Squibb K.K., Ignyta, Janssen, Loxo, Sysmex, Amgen, Thermo Fisher Scientific, Daiichi Sankyo Co Ltd, NEC Corporation, Turning Point Therapeutics

Victoria Soldatenkova

Employment: Lilly

Leadership: Infinity Pharmaceuticals (I)

Stock and Other Ownership Interests: Lilly

Sylwia Szymczak

Employment: Lilly

Stock and Other Ownership Interests: Lilly

Scott S. Barker

Employment: Lilly

Stock and Other Ownership Interests: Lilly

Tarun Puri

Employment: Lilly

Stock and Other Ownership Interests: Lilly

Aimee Bence Lin

Employment: Lilly (I)

Stock and Other Ownership Interests: Lilly (I)

Patents, Royalties, Other Intellectual Property: Co-inventor on a patent application related to selpercatinib activity

Herbert Loong

Consulting or Advisory Role: GlaxoSmithKline, Roche/Genentech, Novartis, Boehringer Ingelheim, Celgene, Lilly, Illumina, Guardant Health, Eisai, Takeda

Speakers' Bureau: Ignyta, Novartis, Guardant Health, Bayer

Research Funding: MSD Oncology (Inst)

Travel, Accommodations, Expenses: Roche, MSD Oncology, Bayer, Pfizer

Benjamin Besse

Research Funding: AstraZeneca (Inst), Pfizer (Inst), Lilly (Inst), Onxeo (Inst), Inivata (Inst), AbbVie (Inst), Amgen (Inst), Blueprint Medicines (Inst), Celgene (Inst), GlaxoSmithKline (Inst), Sanofi (Inst), Takeda (Inst), Cristal Therapeutics (Inst), Daiichi Sankyo (Inst), Janssen Oncology (Inst), OSE Immunotherapeutics (Inst), BeiGene (Inst), Boehringer Ingelheim (Inst), Roche/Genentech (Inst), Tolero Pharmaceuticals (Inst), 4D Pharma (Inst), Aptitude Health (Inst), Cergentis (Inst), Chugai Pharma (Inst), Genzyme (Inst), Ipsen (Inst), Turning Point Therapeutics (Inst), Eisai (Inst)

No other potential conflicts of interest were reported.